ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0733

Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis

Ivan Foeldvari1, Jens Klotsche2, Sheila Angeles-Han3, Jordi Anton4, Gabriele Simonini5, Nadine Groesch2 and Jean Baer6, 1Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 2German Rheumatism Research Center, Berlin, Germany, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Sant Joan de Déu Hospital, Madrid, Spain, 5Anna Meyer Children's Hospital, Firenze, Italy, 6Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany

Meeting: ACR Convergence 2020

Keywords: Juvenile idiopathic arthritis, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: Pediatric Rheumatology – Clinical Poster II: JIA

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile idiopathic arthritis associated uveitis (JIAU) is the most common extra-articular manifestation of JIA, and occurs in approximately 10% of affected children.  Although there are effective medications to treat JIAU, guidelines and large studies that inform of tapering treatment after disease remission are lacking.

Methods: We surveyed vie email international pediatric rheumatologists: 1. Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC), 2. Pediatric Rheumatologic Email-Listserve, 3. CARRA uveitis workgroup, and international ophthalmologic specialized in children with JIAU.  Survey questions focused on the definition of remission, duration of remission prior to initiation of medication tapering, and method of tapering. Specific medications included methotrexate (MTX), adalimumab (ADA), infliximab (IFX), abatacept (ABA), and tocilizumab (TOC).

Results: Of 45 responses, 88% were from pediatric rheumatologists with a mean work experience of 18 years. The regional distribution was 31 form Europa, 9 from North-America, 3 from South-America and 2 from Asia. The responding colleagues managed a mean number of 43 JIAU patients.  Remission on medication was defined as no cells in the anterior chamber (78%), followed by no need for eye drops (36%), and no uveitis flares (32%).  Tapering practices were described for MTX monotherapy (100%) ADA (100%), IFX (80%), TOC (56% [25% s.c.]) and ABA (46% [30% s.c.]).

Standardized protocol for tapering exists in 32% of centers for MTX, in 26% for ADA, and 20% for IFX. The timepoint for tapering was after 6 months of remission on medication by  14% of respondents, 12 months for 38%, 24 months for 56% and 36 months for 12%.

MTX was tapered by dose in 42%, dose and interval in 40%, and interval in 15%. The lowest dose of MTX was 6mg/m2/week at the time of tapering and the longest mean interval 2.5 weeks (1 to 4 weeks).  ADA was first tapered to every 3 weeks by 76% of the responders and then to every 4 weeks by 49% before discontinuing. Fewer respondents used or tapered IFX, TOC or ABA. Around 65% tapered the interval and 20% tapered the dose and interval for ABA, 26% for TOC and 37% IFX

There were differences in the duration of tapering prior to discontinuation of specific medications.  For ADA it was 6 months in 62%, 12 months in 36% ,and 24 months in 10%.   For IFX it was 6 months in 27%, 12 months in 45%, and 24 months in 33%. For TOC it was 40% after 4 weeks, 87% after 6 weeks and 53% after 24 weeks. For ABA i.v.  it was 30% after 8 weeks, and 90% after 12 weeks.

If combination therapy was used, 36% tapered the bDMARD first, 62% csDMARD first, and 12% both simultaneously.

Conclusion: This is the first survey to describe “real world” medication tapering and discontinuation practices of pediatric rheumatologists and ophthalmologists globally. Most physicians start to taper medication after 24 months of remission on medication and discontinue after the 6 to 12 months of tapering.


Disclosure: I. Foeldvari, Sanofi, 5, Chugai, 5, Amgen, 5, GSK, 5, Lilly, 5, BMS, 5, Abbvie, 5, Novartis, 5, gilead, 5; J. Klotsche, None; S. Angeles-Han, Nation Institutes of Health, 2, Emory University, 7, Knights Templar Eye Foundation, 2, Emory University, 2; J. Anton, Sobi, 1, 2, 3, Novartis, 1, 2, 3, GSK, 1, 2, 3, Pfizer, 1, 2, BMS, 1, Chemocentryx,, 1, Lilly, 1, Novimmune, 1, Sanofi, 1, Roche, 1; G. Simonini, Novartis, 5, 8, AbbVie, 5, 8; N. Groesch, None; J. Baer, None.

To cite this abstract in AMA style:

Foeldvari I, Klotsche J, Angeles-Han S, Anton J, Simonini G, Groesch N, Baer J. Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/practice-patterns-for-tapering-medications-in-the-treatment-of-jia-associated-uveitis/. Accessed April 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/practice-patterns-for-tapering-medications-in-the-treatment-of-jia-associated-uveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.